Carnitine-Acylcarnitine Translocase Deficiency, Gene Mutation Analysis
Carnitine-Acylcarnitine Translocase (CACT) is located on the short arm of chromosome 3 (3p21.31) and belongs to SLC25 gene family, SLC25A20 and is mainly expressed in heart, liver, and skeletal muscle. The enzyme carnitine-acylcarnitine translocase is essential for the transport of long-chain fatty acids into mitochondria.
CACT Deficiency is a rare autosomal recessive disorder. CACT and severe CPT2 deficiency have identical clinical manifestations and blood acylcarnitine profiles in the neonatal period and are difficult to differentiate. Neonates with CACT Deficiency manifest with hypoketotic hypoglycemia, neurological damage, cardiomyopathy, hepatic failure, skeletal myopathy, rhabdomyolysis, renal dysfunction, hyperammonemia, coma and death.
- Confirmation of CACT deficiency.
- Carrier screening for CACT deficiency
- Prenatal diagnosis of CACT deficiency
Negative for mutation analyze (No reportable variants were identified)
Whole blood in EDTA
Stability
- Room: 3-5 days
- Refrigerated: 7-14 days
- Other specimens: Saliva, Buccal swab, skin biopsy.
- J Hum Gene.2013 Dec;58(12):788-93. [PMID: 24088670]
- Hum Mutat. 2004 Oct;24(4):312-20.[ PMID: 15365988]
- Medicine (Baltimore). 2017 Nov; 96(45): e8549. [PMID: 29137068]
- Acta Paediatr. 2003 Apr; 92(4):501-4. [PMID: 12801121]